Capecitabine
Triple-Negative Breast Carcinoma
Explore 428 assets in Triple-Negative Breast Carcinoma →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
National University Hospital, Singapore
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07533123CT.gov A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care | — | Recruiting | — | — | — |
NCT07340541CT.gov Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies | — | Recruiting | — | — | — |
NCT07161791CT.gov Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06732323CT.gov A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06966700CT.gov A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | — | Recruiting | — | — | — |
NCT07021261CT.gov Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients | — | Not Yet Recruiting | — | — | — |
NCT06829199CT.gov A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) | — | Withdrawn | — | — | — |
NCT05973864CT.gov Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery | — | Recruiting | — | — | — |
NCT06134375CT.gov A Study of Tetrathiomolybdate (TM) Plus Capecitabine | — | Recruiting | — | — | — |
NCT06568692CT.gov A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | — | Recruiting | — | — | — |
Show 51 more trialsShow fewer
NCT06771609CT.gov Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer. | — | Recruiting | — | — | — |
NCT06519370CT.gov FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT06533384CT.gov PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC | — | Recruiting | — | — | — |
NCT06393374CT.gov Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | — | Recruiting | — | — | — |
NCT06382142CT.gov A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02) | — | Active Not Recruiting | — | — | — |
NCT06355037CT.gov Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06355024CT.gov Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT06245889CT.gov PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC | — | Recruiting | — | — | — |
NCT06385990CT.gov Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy | — | Recruiting | — | — | — |
NCT06279364CT.gov A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06229067CT.gov Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT05774886CT.gov Implantable Microdevice for TNBC - Pilot Study | — | Withdrawn | — | — | — |
NCT05806060CT.gov Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT05760378CT.gov Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. | — | Recruiting | — | — | — |
NCT05633654CT.gov Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | — | Recruiting | — | — | — |
NCT05390476CT.gov Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial | — | Unknown | — | — | — |
NCT05438706CT.gov A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer | — | Unknown | — | — | — |
NCT05134194CT.gov A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer | — | Terminated | — | — | — |
NCT05336721CT.gov A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC | — | Terminated | — | — | — |
NCT05007106CT.gov MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | — | Completed | — | — | — |
NCT04849364CT.gov Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer | — | Terminated | — | — | — |
NCT04745975CT.gov Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer | — | Unknown | — | — | — |
NCT04443348CT.gov Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) | — | Active Not Recruiting | — | — | — |
NCT04595565CT.gov Sacituzumab Govitecan in Primary HER2-negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04464174CT.gov Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer | — | Completed | — | — | — |
NCT04664829CT.gov The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC | — | Completed | — | — | — |
NCT04333706CT.gov A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) | — | Recruiting | — | — | — |
NCT04501523CT.gov A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC | — | Recruiting | — | — | — |
NCT04395989CT.gov An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. | — | Unknown | — | — | — |
NCT04335669CT.gov NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC | — | Active Not Recruiting | — | — | — |
NCT04159142CT.gov Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer | — | Recruiting | — | — | — |
NCT03997968CT.gov A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | — | Completed | — | — | — |
NCT03818685CT.gov Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease | — | Unknown | — | — | — |
NCT03812393CT.gov Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast | — | Unknown | — | — | — |
NCT05089643CT.gov Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer | — | Unknown | — | — | — |
NCT03853707CT.gov Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT03775928CT.gov Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer | — | Unknown | — | — | — |
NCT03805399CT.gov FUSCC Refractory TNBC Umbrella (FUTURE) | — | Unknown | — | — | — |
NCT03387085CT.gov QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | — | Terminated | — | — | — |
NCT03383679CT.gov Study on Androgen Receptor and Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT03371017CT.gov A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer | — | Completed | — | — | — |
NCT03175666CT.gov QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy | — | Withdrawn | — | — | — |
NCT03044730CT.gov Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery | — | Unknown | — | — | — |
NCT02672475CT.gov Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT02734290CT.gov Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02555657CT.gov Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | — | Completed | — | — | — |
NCT02419495CT.gov Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT01997333CT.gov Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT01969032CT.gov Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT01042379CT.gov I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | — | Recruiting | — | — | — |
NCT03304756CT.gov Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer With CAP Regimen | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Triple-Negative Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Capecitabine (this asset) | National University Hospital, Singapore | P3 | BB · 64 |
| Carboplatin | M.D. Anderson Cancer Center | P4 | BB |
| Capivasertib | AstraZeneca | P3 | BB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P4 | BB |
| Veliparib | National Cancer Institute (NCI) | P3 | BB |
| Enzalutamide | Nuvation Bio Inc. | P2 | BB |
| Atezolizumab | European Institute of Oncology | P3 | BB |
| Famitinib | Fudan University | P3 | BB |
| Epirubicin | M.D. Anderson Cancer Center | P4 | BB |
+42 more in the Triple-Negative Breast Carcinoma cohort
Other indications for Capecitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Carcinoma | — | P4 | BBB · 73 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 72 |
| Colorectal Neoplasm | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Capecitabine in Triple-Negative Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/capecitabine-triple-negative-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →